Swiss Auto Components Stock News

SWX:AERO
SWX:AEROAerospace & Defense

Assessing Montana Aerospace (SWX:AERO) Valuation After First Quarter 2026 Earnings Update

Montana Aerospace (SWX:AERO) moved into focus after reporting first quarter 2026 results, with sales of €249.34 million and net income of €10.34 million, compared with €240.48 million and €5.27 million a year earlier. See our latest analysis for Montana Aerospace. At a share price of CHF22.55, Montana Aerospace has seen its short term share price weaken, with the 30 day share price return down 11.39% and the 90 day share price return down 33.68%. However, the 3 year total shareholder return...
SWX:SREN
SWX:SRENInsurance

3 European Dividend Stocks With Up To 5.9% Yield

As European markets grapple with geopolitical tensions and inflationary pressures, the pan-European STOXX Europe 600 Index recently saw a decline of 0.85%, reflecting broader economic concerns. Despite these challenges, robust earnings growth in certain sectors highlights opportunities for investors seeking stable income through dividend stocks. In such an environment, a good dividend stock is characterized by consistent payout history and strong fundamentals that can withstand market...
SWX:PGHN
SWX:PGHNCapital Markets

A Look At Partners Group Holding (SWX:PGHN) Valuation After Recent Mixed Share Performance

Recent share performance and business scale Partners Group Holding (SWX:PGHN) has recently shown mixed share performance, with the stock up 1.1% over the past day and 2.9% over the past week, while down over the past month and past 3 months. At a last close of CHF 909.60 and a market value of about CHF 23.5b, the company is among the larger listed alternative asset managers. It is backed by CHF 2,554.8m in revenue and CHF 1,260.7m in net income. See our latest analysis for Partners Group...
SWX:LONN
SWX:LONNLife Sciences

Lonza Group (SWX:LONN) Valuation Check After Dividend Increase And Cell Culture Media Growth Tailwinds

Lonza Group (SWX:LONN) has drawn fresh attention after shareholders approved a CHF 5.00 per share dividend, a 25% year-on-year increase, alongside board and remuneration committee changes at the 8 May 2026 Annual General Meeting. See our latest analysis for Lonza Group. Alongside the higher dividend and refreshed board, Lonza Group’s 1-day share price return of 0.92% and 7-day share price return of 3.86% come against a year-to-date share price return that is down 8.05%, and a 1-year total...
SWX:ABBN
SWX:ABBNElectrical

ABB (SWX:ABBN) Valuation Check After IE6 Motor Launch And $200 Million Grid Investment

ABB (SWX:ABBN) has put fresh attention on its stock after unveiling an IE6 hyper efficiency motor for hazardous areas and outlining a $200 million program to expand medium voltage manufacturing across Europe. See our latest analysis for ABB. The recent IE6 motor launch and the $200 million medium voltage expansion have landed against a strong backdrop, with ABB’s share price at CHF81.34 and a 30 day share price return of 9.53%, while the 1 year total shareholder return of 73.45% and 5 year...
SWX:SOON
SWX:SOONMedical Equipment

Sonova Holding (SWX:SOON) Margin Slippage Tests Bullish Cost Efficiency Narrative

Sonova Holding (SWX:SOON) has just reported first half FY 2026 revenue of CHF1.8 billion and basic EPS of CHF3.16, alongside trailing twelve month revenue of CHF3.6 billion and EPS of CHF9.02 that sit against a mixed track record of earnings and margin trends. The company has seen first half revenue move from CHF1.8 billion in FY 2024 to CHF1.8 billion in FY 2025 and CHF1.8 billion in FY 2026, while basic EPS over those same first half periods shifted from CHF5.97 to CHF3.50 and then CHF3.16...
SWX:ROP
SWX:ROPPharmaceuticals

Roche ASCO 2026 Breast Cancer Data May Reshape Outlook For Shares

Roche Group (SWX:ROP) and Genentech plan to present new clinical data across nine cancer medicines at the 2026 ASCO Annual Meeting. The program includes breast cancer results that may be important for clinical practice, with a focus on giredestrant, a selective estrogen receptor degrader. Data span both investigational and approved therapies, including antibody drug conjugates, bispecific antibodies, and treatments for several cancer types. The breadth of readouts could influence treatment...
SWX:BARN
SWX:BARNFood

Barry Callebaut (SWX:BARN) Valuation After Cacao Max And ChoViva Product Launches

Barry Callebaut (SWX:BARN) has put product development in the spotlight at the 2026 Sweets & Snacks Expo by reshaping its compound range into a new Cacao Coatings & Inclusions category and launching Cacao Max and cocoa free ChoViva. See our latest analysis for Barry Callebaut. Investors have reacted positively to Barry Callebaut’s recent product announcements, with the share price delivering a 1 month share price return of 12.81% even though the 3 year total shareholder return is down 31.70%,...
SWX:SOON
SWX:SOONMedical Equipment

Sonova Holding (SWX:SOON) Is Up 9.8% After Record Dividend And Strong Normalized EBITA Growth - What's Changed

Sonova Holding AG has released its full-year results for the period ended March 31, 2026, reporting sales of CHF 3,605.9 million, net income of CHF 430.6 million, and announcing an annual dividend of CHF 4.70 per share payable on June 23, 2026. Despite lower reported net income year-on-year, the company achieved 5.9% sales growth and a 17.3% increase in normalized EBITA in local currencies, primarily driven by its Hearing Instruments segment and supported by business reshaping and the...
SWX:CMBN
SWX:CMBNConsumer Finance

European Dividend Stocks To Consider For Income

As European markets navigate the challenges of geopolitical tensions and inflationary pressures, investors continue to seek stability and growth through dividend stocks. In such a climate, selecting stocks with robust earnings growth and consistent dividend payouts can be an effective strategy for those looking to generate income while potentially mitigating volatility.
SWX:AMS
SWX:AMSSemiconductor

A Look At Ams-OSRAM (SWX:AMS) Valuation After Q1 2026 Earnings And Softer Revenue Guidance

ams-OSRAM (SWX:AMS) drew fresh attention after reporting first quarter 2026 results that showed lower sales and a wider net loss, alongside new guidance indicating slightly softer full-year revenue due to divestments and currency effects. See our latest analysis for ams-OSRAM. The Q1 results and softer full year guidance came after a sharp rebound in the stock, with a 30 day share price return of 50.80% and a 90 day share price return of 119.51%. However, the 3 year total shareholder return...
SWX:NOVN
SWX:NOVNPharmaceuticals

Assessing Novartis (SWX:NOVN) Valuation After Promising Pluvicto Prostate Cancer Data

Novartis (SWX:NOVN) is back in focus after new clinical data showed its radioligand therapy Pluvicto, when added to standard treatment, cut the risk of PSA progression by 58% in a specific prostate cancer setting. See our latest analysis for Novartis. Alongside the Pluvicto data and a series of US manufacturing and research expansions, Novartis has seen firm investor interest, with the share price at CHF117.2 and an 8.02% year to date share price return, while the 1 year total shareholder...
SWX:SCMN
SWX:SCMNTelecom

Is It Too Late To Consider Swisscom (SWX:SCMN) After A 27% One-Year Rally?

Investors may be asking whether Swisscom at CHF676.0 is offering fair value right now, or if the recent momentum has already priced in the opportunity. The stock has returned 1.0% over the past week, 3.9% over the past month, 16.8% year to date, and 27.2% over the last year, which naturally raises questions about how much of its potential is already reflected in the price. Recent attention on Swisscom has focused on its role as a major Swiss telecom operator and how investors view its...
SWX:ADEN
SWX:ADENProfessional Services

Assessing Adecco Group (SWX:ADEN) Valuation After Q1 2026 Earnings And AI Productivity Push

Q1 earnings spark fresh look at Adecco Group stock Adecco Group (SWX:ADEN) just released Q1 2026 results, with organic revenue growth, higher net income and EBITA, and market share gains in the Americas and APAC putting the stock back in focus. See our latest analysis for Adecco Group. Despite the Q1 2026 earnings lift, the share price has fallen 36.36% year to date, contributing to a 33.17% decline in 1 year total shareholder return and signalling fading momentum despite improving...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is Novartis’ US Radioligand Manufacturing Buildout (SWX:NOVN) Altering Its Investment Case?

In early May 2026, Novartis broke ground on a new 46,000 sq. ft radioligand therapy manufacturing facility in Denton, Texas, part of its US$23.00 billion US manufacturing and research expansion and its fifth radioligand therapy site nationwide. This build-out of a coast-to-coast radioligand therapy network highlights how Novartis is tying manufacturing proximity and reliability directly to complex cancer treatment delivery for US patients. We will now explore how this expanded US radioligand...
SWX:LAND
SWX:LANDElectronic

Landis+Gyr Group (SWX:LAND) Valuation Check After Annual Loss And Weak Long Term Returns

Landis+Gyr Group (SWX:LAND) has recently drawn attention after its latest financial data showed annual revenue of $1,625.8m and a net loss of $136.1m, prompting investors to reassess the smart metering specialist. See our latest analysis for Landis+Gyr Group. At a share price of CHF47.85, Landis+Gyr Group has seen short term share price momentum pick up, with a 7 day share price return of 6.93%. However, longer term total shareholder returns over 3 and 5 years remain weak and suggest...
SWX:TEMN
SWX:TEMNSoftware

Assessing Temenos (SWX:TEMN) Valuation After New Banking Deals And AI Product Launches

Temenos (SWX:TEMN) is back in focus after a cluster of fresh contracts and product launches, including new core banking deals with Habib Bank Limited and Reliance Bank, as well as extended collaborations with First Abu Dhabi Bank and Questrade Financial Group. See our latest analysis for Temenos. The recent stream of banking deals and AI product launches comes against a mixed backdrop. The share price stands at CHF71.45, with a 90 day share price return of 11.29%, but a year to date share...